While Notch signaling has been proposed to play a key role in fibrosis, the direct molecular pathways targeted by Notch signaling and the precise ligand and receptor pair that are responsible for kidney disease remain poorly defined.
Introduction
One in ten people worldwide suffers from chronic kidney disease (CKD) (1, 2) . Fibrosis is the final common pathway and histological manifestation of CKD which is characterized by the accumulation of collagen, activated myofibroblasts, inflammatory cells, epithelial cell dedifferentiation, and loss of vascular supply in the kidney (3) (4) (5) .
The mechanism of fibrosis is a hotly debated issue. Renal tubule epithelial cells (RTEC) appear to play key role in fibrosis development. Direct in vivo genetic manipulations of RTEC is both sufficient to induce or to ameliorate fibrosis development in mice (6) (7) (8) . Injury to RTECs is usually agreed to be a proximal lesion in the downstream cascade that eventually results in fibrosis (9, 10) . Recent studies highlighted the reemergence of developmental pathways in fibrosis including Notch, Wnt and Hedgehog in response to severe tubule injury (11) (12) (13) (14) (15) (16) . While chronic activation of Notch plays a key role in development and regeneration of the kidney, sustained (tonic) expression of Notch in RTEC will expand the progenitor (transit) amplifying pool but eventually block full differentiation of RTEC.
Epithelial dedifferentiation, due to the lack of expression of key transporter and functional proteins will lead to CKD development. Direct targets of Notch signaling and the exact mechanism of Notchinduced RTEC dedifferentiation is not fully understood.
Notch signaling is a highly conserved cell-cell communication mechanism that regulates tissue development, homeostasis, and repair. In mammals, there are four Notch receptors (NOTCH 1-4) and five canonical ligands, Jagged (JAG1, 2) and Delta-like ligand (DLL1, 3, 4) . Upon ligand binding, the Notch intracellular domain (NICD) travels to the nucleus, binds to RBPJ (recombination signal binding protein for immunoglobulin kappa J region), and mediates gene transcription (17) . While Notch signaling plays an important role in a multitude of disease development, it also has an important homeostatic function (16) . Systemic pharmacological targeting of NOTCH has been developed and is in clinical trials for various solid cancers (18) . Most of these drugs have been associated with significant toxicities that which likely limit their development for chronic, slowly progressing conditions such as fibrosis (18) (19) (20) (21) . New results on the other hand suggest that while different Notch ligands and receptors are homologous, they seem to exert isoform-specific functions (16) . By using antibodies to specifically target Notch signaling, the Jones' group found that inhibition of JAG1, acting together with NOTCH2, reduces tumor burden in a mouse model of primary liver cancer (22) . Tran et al demonstrated the dominant role of DLL4-NOTCH1 signaling in T-cells during graft-versus-host disease using a ligand-targeted antibody strategy (23) . Ligand-specific targeting strategies were able to dissociate disease causing and homeostatic functions of Notch signaling; therefore, they could offer novel therapeutic strategies.
Our previous results indicated that increased and sustained tubular epithelial Notch signaling following injury plays a key role in the development of the renal tubulointerstitial fibrosis (TIF) (8, (24) (25) (26) (27) (28) . Global and systemic inhibition of Notch signaling using small molecular blockers of the gamma secretase pathway ameliorated fibrosis in the folic acid, unilateral ureteral obstruction, and HIVinduced kidney fibrosis models (29) (30) (31) (32) (33) (34) . Similarly, mice with genetic deletion of Rbpj in renal tubule cells were protected from kidney fibrosis development. As RBPJ is a common partner for all Notch receptors, these studies were unable to identify the specific Notch ligand/receptor pair responsible for the profibrotic effect of Notch signaling. Furthermore, RBPJ also has Notch independent activity. Identification of specific ligands and receptors for kidney fibrosis therefore remains a critically important issue.
Here, we analyzed several mouse models and patient samples with kidney disease to understand the expression of Notch ligands and receptors. We generated mouse models with genetic deletion of individual Notch ligands and receptors, and finally, we identified direct targets of Notch signaling. We show that RTEC expression of Jag1 acting together with Notch2 leads to metabolic reprogramming of RTEC via Tfam, resulting in epithelial dedifferentiation and fibrosis development.
Results

Increased Jag1 and Notch2 expression in RTEC of mice and patients with kidney fibrosis
To identify Notch ligands and receptors responsible for fibrosis development, we first evaluated results from unbiased gene expression (RNA sequencing) studies of mice with kidney fibrosis, including folic acid (FA) nephropathy, unilateral ureteral obstruction (UUO) model, and podocytespecific expression of APOL1 risk variants (Figure 1 , A-C) (35) (36) (37) . Amongst the different ligands, Jag1 transcript level was the highest in whole kidney lysates while the level of Dll3 was too low to detect. Expression of Jag1 was consistently and significantly increased in kidneys of all examined CKD models (Figure 1 , A-C). Of the Notch receptors, we found Notch2 had the highest expression in the kidney and its level was consistently increased in all fibrosis models.
To understand the human translatability of the studied mouse models, we have analyzed gene expression changes in 95 microdissected human kidney tubule samples. The dataset included microarray samples from healthy, diabetic, and hypertensive subjects, and patients with varying degrees of fibrosis and chronic kidney disease (38) . Among all tested Notch ligands, JAG1 expression showed significant positive correlation with the degree of fibrosis (P=0.003) (Table 1; Figure 1D ).
We also found a positive association between the expression of NOTCH2 with the degree of interstitial fibrosis (P=0.02) ( Figure 1E) .
Given that Notch is activated by proteolytic cleavage, we then confirmed the increase in cleaved protein expression of JAG1 and NOTCH2 in kidneys with fibrosis. Immunostaining studies indicated increased protein expression of JAG1 in kidney tubule of human TIF samples. Only few cells were positive for JAG1 in healthy human kidney samples, but its expression was much increased in RTEC of kidneys obtained from CKD subjects ( Figure 1F) . Similar results were obtained for NOTCH2 ( Figure 1G) .
We next examined JAG1 and NOTCH2 level in kidneys of FA-induced kidney fibrosis mice.
Double immunostaining of JAG1 with kidney-segment-specific markers identified JAG1-positive cells in LTL (lotus lectin, a marker for proximal tubule) and PNA (peanut agglutinin, a marker for distal tubule/loop of Henle) positive tubules, but not in AQP2 (aquaporin 2, a marker for collecting duct) expressing tubule segments. We also identified NOTCH2-positive cells in LTL-, PNA-and AQP2positive tubule segments, indicating that most examined tubule segments expressed NOTCH2 (Figure   1 , H and I). In summary, Jag1 and Notch2 were the highest expressed Notch ligands and receptors in whole kidney lysates, and both their transcript and protein levels showed a consistent increase in kidney tubule cells in patient samples and in animal models.
TIF development is mediated by tubule epithelial expression of Jag1 and Notch2
Next, we studied whether increased JAG1 expression observed in CKD renal tubule cells contributes to fibrosis development. Therefore, we crossed the Jag1 flox/flox animals with mice expressing Cre recombinase under the cadherin 16 promoter to generate animals with Jag1 deletion in RTEC (Ksp cre /Jag1 flox/flox ) (Figure 2A ) (39) . Ksp cre /Jag1 flox/flox mice showed lower Jag1 expression but no significant histological alterations at baseline ( Figure 2B) . Kidney fibrosis was induced by FA injection. We found that 7 days after FA injection, kidney histology was markedly improved in the Our unbiased analysis identified NOTCH2 as a Notch receptor with the strongest correlation with fibrosis. We next studied the role of Notch2 in kidney fibrosis. We generated mice with RTEC-specific deletion of Notch2 by mating the Notch2 flox/flox mice with the Ksp cre mice (Figure 3A) . Animals were born with expected Mendelian frequency and histological analysis showed no significant difference between control and conditional knock-out mice (Figure 3B ). Folic acid injection was used to induce kidney fibrosis. The expression of Notch2 Notch3 and HeyL levels were significantly decreased while Notch1 and Jag1 levels were unchanged in FA-treated Ksp cre Notch2 flox/flox mice (Figure 3C) . We found marked structural improvement when PAS-stained kidney sections of folic acid injected control and Ksp cre Notch2 flox/flox were compared ( Figure 3B) . In conjunction, levels of the profibrotic genes Fibronection, Vimentin, Collagen1, 3, Acta2, Snai1 and Snai2 were significantly reduced in tubulespecific Notch2 knock-out animals ( Figure 3D ).
To understand whether this effect is specific for Jag1 and Notch2, we tested the effect of genetic deletion of Notch1 and Notch3. Tubule-specific Notch1 knock-out mice was generated by mating the 
Jag1/Notch2 in RTEC induces dedifferentiation and proliferation
In order to understand the downstream molecular pathways regulated by Jag1/Notch2, we turned to an in vitro system. TGF-1 is one of the most powerful profibrotic cytokines and a known inducer of Notch signaling in epithelial cells by Smad3 (8, 40) . TGF-1 treatment significantly increased Jag1 expression in primary culture of RTECs (Figure 4A) , indicating that TGF-1 is an upstream Notch regulator in tubule cells. Similar to the in vivo kidney data, the expression of Notch2 was the highest amongst the different Notch receptors in cultured RTECs.
Furthermore, to study the role of JAG1 specifically, we have set-up a co-culture system by mixing RTEC with JAG1-expressing or control stromal cells (Figure 4, B 
Tfam is direct target of Notch
To understand the direct molecular targets of Notch signaling, we have examined RBPJ chromatin immunoprecipitation datasets (ChIP-seq) (41) . To filter out functionally important binding that are also associated with gene expression changes in vivo, we correlated the ChIP-seq results with changes observed by transcriptome analysis of kidneys from tubule-specific Notch1 transgenic mice (Pax8 rtTA /TRE ICNotch1 ) (8) . This combined analysis identified 79 RBPJ-binding sites and those gene expression also changed following in vivo NOTCH expression in tubule cells (56 increase and 23 decrease RBPJ-binding sites) (Supplemental Figure 3A ; Supplemental Table1 and 2). Gene ontology (GO) classification of genes with direct RBPJ binding and RTEC gene expression changes indicated enrichment for metabolic pathways (i.e. Rxra, Tfam, Acot12, Ndufa10, etc) ( Table 2) .
Epidermal growth factor (EGF, encoded by Egf) was one of the top differentially expressed genes in Pax8 rtTA /TRE ICNotch1 mice (Supplemental Table2) with lower expression in Notch transgenic animals.
We found that RBPJ could directly bind to the Egf regulatory region (Supplemental Figure 4A) . EGF showed strong negative correlation with kidney fibrosis score in human kidney samples (P=8.91×10 -7 ) (Supplemental Figure 4B) . Egf was also persistent decreased in FA, UUO, and APOL1 CKD mouse models (Supplemental Figure 4 , C-E). To understand the role of EGF, we added Recombinant Human EGF to culture medium. We found that exogenous EGF was unable to ameliorate Notchinduced expression of Acta2 and Snai1 (Supplemental Figure 4F) . In summary, we were unable to connect the Notch-induced Egf changes to fibrosis development. While previous studies indicated that peroxisome proliferator-activated receptor γ coactivator-1α (PGC1α, encoded by the gene Ppargc1a) can rescue Notch-induced kidney fibrosis, the reduced PGC1α cannot be responsible for Notch-induced cellular dedifferentiation as the PGC1α knock-out mice has no renal phenotype at baseline (42, 43) . To understand whether reduced Tfam expression plays a role in tubule epithelial dedifferentiation, we generated a new mouse model with tubuleepithelial-specific deletion of Tfam by mating the Tfam flox/flox and Ksp Cre mice (Supplemental Figure   3B ). We found fewer than expected Ksp Cre Tfam flox/flox mice in the litter when compared to heterozygous or wild type controls ( Table 3) (Figure 5F) . Overall, we found a direct binding of RBPJ into the Tfam promoter and reduced Tfam expression following Notch activation. Tfam expression in tubule cells were critically important for kidney function as mice with genetic deletion of Tfam in tubule cells died shortly after birth.
Tfam can rescue Notch-induced metabolic defect and downstream profibrotic changes
As we identified Tfam as a direct Notch target, we hypothesized that the widespread effect of Notch on gene expression and RTEC dedifferentiation is mediated by direct metabolic reprogramming. To understand the functional consequences of Notch-induced reduction of Tfam expression, we have examined mitochondrial function in RTEC. RTEC exclusively rely on mitochondrial fatty acid oxidation (FAO) as their energy source (44, 45) . First, we examined Tfam expression in vitro following Jag1/Notch2 activation. Tfam expression was lower in RTEC-cultured in cells treated with TGF-1 and also in the presence of JAG1-expressing stromal cells (Figure 6A; Supplemental Figure 5A ). We found that increased Notch activation was associated with a decrease in FAO of tubule cells confirming that Tfam is a direct Notch target. Increasing Tfam expression in RTEC improved the FAO defect both in the TGF-1-induced Notch activation models and in the JAG1 co-culture system (Figure 6, B and C; Supplemental Figure 5, B and C) , thus indicating that Tfam is functionally important in mediating the Notch-induced metabolic reprogramming.
Furthermore, the improved FAO and mitochondrial content significantly ameliorated the Notch induced profibrotic gene expression changes (Figure 6D; Supplemental Figure 5D ). To prove that the rescue effect was related to improved FAO, we have also treated cells with the peroxisome proliferator-activated receptor  (PPAR) agonist, fenofibrate. We found that fenofibrate could rescue Jag1-induced fibrosis (Supplemental Figure 6, A and B) , indicating the key role of metabolic changes in Notch induced fibrosis.
Finally, we have examined whether Jag1 and Notch2 deletion can rescue from the metabolic defect observed in mouse kidney fibrosis samples. We found that Tfam expression was decreased in the FAinduced kidney fibrosis in control groups. Genetic deletion of Jag1 and Notch2 prevented the decrease in Tfam expression and downstream fibrosis development (Figure 6, E and F) . On the other hand, mice with genetic deletion of Notch1 and Notch3 were not protected from fibrosis induced a decrease in Tfam expression (Supplemental Figure 5, E and F) . In summary, these results strongly indicate that the Notch-induced inhibition of Tfam and downstream metabolic reprogramming are responsible for the profibrotic effect of Notch both in vivo and in vitro (Figure 7) .
Discussion
Here we showed that the Notch ligand Jag1 and the Notch receptor Notch2 expression in renal tubule cells play a key role in kidney fibrosis development. While previous studies from our and other groups have already suggested the contribution of Notch signaling in chronic kidney disease, most prior studies have used models with global inhibition or activation of Notch signaling (8, 46, 47) . While such studies were instrumental to the understanding of the biology of kidney fibrosis, they did not represent clinically translatable strategies for conditions such as fibrosis, as long-term systemic inhibition of Notch signaling are associated with significant side effects (18) . Gamma secretase inhibitors are associated with significant intestinal toxicity as Notch signaling plays a key role in intestinal cell differentiation. To circumvent these issues, receptor and ligand isoform specific targeting are emerging with improved side effect profiles.
Here, we used mice with tubule specific genetic deletion of Notch1, Notch2 and global deletion of Notch3, and we show that only mice with tubule specific loss of Notch2 is protected from kidney fibrosis. Similarly, genetic removal of Jag1 in tubule epithelial cells were also protective in animal models. These results are consistent with unbiased gene expression analysis results that indicated that the expression of Jag1 and Notch2 were the highest in mouse and human kidneys. The expression of JAG1 and NOTCH2 showed the strongest correlation with kidney fibrosis in human kidneys. In addition to our current direct genetic models, several other prior studies suggested Notch2 as an indirect target of pharmaceutical interventions for kidney fibrosis. For example, the Lorenzen group showed the miR-21 is an important upstream regulator of Notch2 and therefore miR-21 antagonist that is currently in clinical studies might also reduce Notch2 activation (48) . Similar studies showed that Klotho deficiency can cause fibrosis via Notch2 activation (49) . It is important to note that isoformspecific Notch receptor targeting has been more difficult to develop than ligand targeting, furthermore one study examining the role of Notch2 in podocytes in nephrotic syndrome indicated some potential benefit (50) . Therefore, ligand targeting such as JAG1 appears to be the most reasonable approach for CKD. Our studies can provide the foundation for the development of novel molecular therapeutics for kidney failure and advance our understanding of the renal effect of JAG1 antagonism based therapies.
Our studies show that Notch directly binds to the metabolic transcription factor Tfam to reprogram tubule epithelial metabolism, and induces tubule epithelial dedifferentiation and proliferation. While prior work indicated the role of metabolic changes in kidney disease development, here we show a direct interaction between Notch and metabolic changes as Tfam is its direct target. Kidney tubules are highly metabolic cells and many prior studies have focused on identification of the key metabolic transcription factor for tubule cells. Studies have demonstrated a decrease in expression of Ppargc1a, Ppara and Pparg (51) . Transgenic expression of Ppargc1a and Ppara showed protection from acute kidney injury or kidney fibrosis indicating the key role of metabolic pathways in kidney function and tubule health (44) . On the other hand, mice with global deletion of Ppargc1a and Ppara did not present with renal abnormalities, thus raising significant doubts that the reduced expression of these transcription factors are actually important for fibrosis development (43, 52) . Here, we show that Tfam is the essential transcription factor for renal tubule cell metabolism. Tubule specific deletion of Tfam in mice results in tubule epithelial dedifferentiation and perinatal lethality. These results indicate that while transgenic expression of Ppargc1a and Ppara showed protection, the key metabolic transcription factor in the kidney is Tfam as no other transcription factor was able to compensate for its loss (51) .
We have also analyzed other targets. We found direct Notch binding to the Egf promoter and subsequent inverse correlation between Notch levels and Egf expression in the kidney. Our in vitro studies failed to establish a causal relationship between Notch-regulated Egf levels and subsequent kidney fibrosis development. Overall, our studies indicate that Notch-induced global changes in differentiation was mediated by the regulation of cellular metabolism rather than individual targeting individual differentiation-associated gene expression. Given the broad transcriptional program Notch needs to regulate, it actually makes sense that regulated cellular metabolism alters cell differentiation states.
Future studies shall aim to understand the mechanism of sustained and excessive Notch activation in CKD. Increased tonic Notch activation is likely important in orchestrating the regenerative response including transit amplification and proliferation. It seems, however, that in CKD, Notch activation is excessive and sustained, which might be caused by the sustained epithelial injury. Overall, our studies indicate that targeting specific Notch ligand JAG1 or NOTCH2 could have important therapeutic potential for the treatment of chronic kidney disease. Gene expression analysis. RNA sequencing data from FA treatment for 3d mouse kidney samples were compared with normal group (GSE65267, GSM1591198-GSM1591199 vs GSM1591206-GSM1591208) (36) . UUO 8d mice were compared with their sham operated group (GSE79443, GSM2095449-GSM2095452 vs GSM2095456-GSM2095458) (37) . Mice with transgenic expression of APOL1 risk variants in podocytes were compared with control littermates (GSE81492, GSM2154804-GSM2154809 vs GSM2154800-GSM2154803) (35) .
Methods
Mice. Mice with
Human samples. 95 tubule compartments of human kidney samples were microdissected from nephrectomies as previously described (ArrayExpress: E-MTAB-5929, E-MTAB-2502) (38) . Fibrosis scores for all samples were quantified by a pathologist using PAS-stained kidney sections. Correlation between fibrosis score and gene expression used a linear regression model adjusted for gender, age, and race.
RNA sequencing. Primary culture of mouse renal epithelial cell and TGF-1 treatment was done as previously described (44) . RNA quality was assessed with the Agilent Bioanalyzer 2100 and only samples with RIN scores above 7 were used for cDNA production. RNA (100 ng) was used to isolate poly(A)-purified mRNA using the Illumina TruSeq RNA Preparation Kit. Single end 50-bp sequencing was performed in an Illumina HiSeq, and the annotated RNA counts (fastq) were calculated by Illumina's CASAVA 1.8.2. Sequence quality was surveyed with FastQC. Adaptor and lower-quality bases were trimmed with TrimGalore. Reads were aligned to the Gencode mouse genome (GRCm38) using STAR-2.4.1d. Read counts for each sample were obtained using HTSeq-0.6.1 (htseqcount).
Staining. Kidneys were harvested from control and FA injected mice or human kidneys. Histological analysis was examined on formalin-fixed, paraffin-embedded kidney sections stained by PAS (periodic acid Schiff). Immunofluorescence staining was performed with antibodies against JAG1 (Santa Cruz#SC9303) and NOTCH2 (Millipore#07-1234) in OCT-embedded frozen kidney sections. Tubule specific markers were used as previously described (53) . Immunohistochemistry staining was performed with antibody against COX IV (Abcam# ab16056) in paraffin-embedded kidney sections. were plated on top of signal-receiving cells at a density equal to the monolayer to establish a direct contact between ligand and receptor. The cells were co-cultured in growth medium for 24 hours. For the rescue experiment, NRK-52E were either transiently co-transfected with TFAM-expressing plasmid and GFP as control or EGF. Transfection efficiency was confirmed by GFP visualization. Following transfection, the cells were co-cultured with either JAG1-expressing L cells or L cells for 24 hours, or were treated with TGF-1 (5 ng/ml) for 48 hours. pCellFree_G03 TFAM was a gift from Dr. Kirill Alexandrov (Addgene plasmid # 67064) (54) . Recombinant Human EGF was purchased from Peprotech.
ChIP-seq. RBPJ ChIP-seq dataset with 6h and 24h Notch activation and inhibition was adapted from cultured cells (GSE37184) (41) .
Oxygen consumption experiment. FAO were studied using SeaHorse Bioscience metabolic analyzer as previously described (44) . We followed manufacturer's instruction to monitor oxygen consumption rate (OCR) in TGF-1-treated NRK52E cells or co-culture system. Briefly, cells were seeded in XF24 
